Development of idraparinux and idrabiotaparinux for anticoagulant therapy

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 811-815

  Harenberg, Job ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atrial fibrillation; Idrabiotaparinux; Idraparinux; Thrombosis

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; BIOTIN; FONDAPARINUX; IDRABIOTAPARINUX; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; WARFARIN;

AREA UNDER THE CURVE; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; ANTITHROMBIN III; ATRIAL FIBRILLATION; AVIDIN; BIOTIN; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HEMORRHAGE; HEPARIN ANTAGONISTS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OLIGOSACCHARIDES; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS; TREATMENT OUTCOME;

EID: 70449598269     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-08-0555     Document Type: Conference Paper

References (36)

1. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 445S-454S. (Pubitemid 351892971)
2. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S. (Pubitemid 351892970)
3. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S. (Pubitemid 351892967)
4. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-5592S.
5. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S-159S.
6. Koopman MM, Büller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003; 254: 335-342.
7. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 234S-256S.
8. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008; 34: 39-57. (Pubitemid 351640881)
9. Prandoni P, Tormene D, Perlati M et al. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin Investig Drugs 2008; 17: 773-777. (Pubitemid 351843619)
10. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-4205. (Pubitemid 28261983)
11. Organon, Sanofi-Synthélabo. Idraparinux sodium. Drug Data Rep 2003; 25: 332.
12. Van Amsterdam RGM, Burggraaf J, Borm GF, et al. A phase I multiple dose study to investigate the safety, tolerance and pharmacokinetics of 10mg S.C. SanOrg34006 in male and female volunteers with a history of VTE, recently discharged from oral anticoagulant treatment. Clinical Trial Report on Protocol 64703. NV Organon. R&DRR NL0028967.
13. Faaij RA, Burggraaf J, Schoemaker RC et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers. Thromb Haemost 1999; Suppl: Abstract 1547.
14. Faaij RA, Burggraaf J, Schoemaker RC, et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers. Thromb Haemost 1999; Suppl: Abstract 2709.
15. Idraparinux sodium. Drug Data Report 2003; 25: 332.
16. PERSIST investigators. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J Thromb Haemost 2004; 2: 47-53.
17. Harenberg J, Jörg I, Vukojevic Y, et al. Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur J Clin Pharmacol 2008; 64: 555-563.
18. Veyrat-Follet C, Vivier N, Trellu M, et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009; 7: 559-565.
19. Ma Q, Fareed J. Idraparinux sodium. Sanofi-Aventis. IDrugs 2004; 7: 1028-1034.
20. Bijsterveld NR, Vink R, Van Arken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the longacting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004; 124: 653-658. (Pubitemid 38297099)
21. The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
22. The van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.
23. Harenberg J, Weiss C, Mikus G, et al. Long elimination half life of idraparinux after termination of therapy explains bleeding in the van Gogh trials. J Thromb Haemost 2008; 6: 890-892.
24. The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet 2008; 371: 315-321.
25. Patents EP 1 322 673 B1/US 6,844,329 B2. http://www.epo.org/ patents/patent-information/european- patent-documents/publicationserver. html.
26. Kang YS, Saito Y, Pardridge WM. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J Drug Target 1995; 3: 159-165.
27. Wilchek M, Bayer EA. The avidin-biotin complex in bioanalytical applications. Anal Biochem 1988; 171: 1-32.
28. Muus CJ, Azar HA. Application of immunochemistry to the diagnosis of human neoplasms in routine histologic sections. Diagn Immunol 1986; 4: 125-139.
29. Huntington JA, McCoy A, Belzar KJ, et al. The conformational activation of antithrombin. A 2.85-A structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem 2000; 275: 15377-15383. (Pubitemid 30337267)
30. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 6: 1697-1706.
31. Burkhart KK, Britt AM. Reversal of toxicity using avidin-based hemoperfusion: a model system in rats using biotinylated melittin. Pharmacology 1995; 50: 307-312.
32. Stoldt HS, Aftab F, Chinol M, Paganelli G, Luca F, Testori A, Geraghty JG. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur J Cancer 1997; 33: 186-192. (Pubitemid 27117712)
33. Trellu M, Perez Y, Ortiz J, et al. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J Thromb Haemost 2007; 5: P-T-678.
34. Buller HR, Destors JM, Gallus AS, et al. Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin. Blood 2008; 112: 18 (Abstract 32).
35. Turpie AG. Fondaparinux: a factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 2004; 5: 1373-1384.
36. de Kort M, Buijsman RC, van Boeckel CA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005; 10: 769-779. (Pubitemid 40744921)